AP1408A - Phenyl yanthine derivatives. - Google Patents

Phenyl yanthine derivatives.

Info

Publication number
AP1408A
AP1408A APAP/P/2001/002071A AP2001002071A AP1408A AP 1408 A AP1408 A AP 1408A AP 2001002071 A AP2001002071 A AP 2001002071A AP 1408 A AP1408 A AP 1408A
Authority
AP
ARIPO
Prior art keywords
derivatives
disorders
phenyl yanthine
yanthine
phenyl
Prior art date
Application number
APAP/P/2001/002071A
Other languages
English (en)
Other versions
AP2001002071A0 (en
Inventor
Susan Mary Daluge
Cynthia Holder Jurgensen
Michael Tolar Martin
Martin Howard Osterhout
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of AP2001002071A0 publication Critical patent/AP2001002071A0/xx
Application granted granted Critical
Publication of AP1408A publication Critical patent/AP1408A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
APAP/P/2001/002071A 1998-08-13 1999-08-11 Phenyl yanthine derivatives. AP1408A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9817623.3A GB9817623D0 (en) 1998-08-13 1998-08-13 Pharmaceutical compounds
PCT/EP1999/005814 WO2000009507A1 (en) 1998-08-13 1999-08-11 Phenyl yanthine derivatives

Publications (2)

Publication Number Publication Date
AP2001002071A0 AP2001002071A0 (en) 2001-03-31
AP1408A true AP1408A (en) 2005-05-06

Family

ID=10837179

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002071A AP1408A (en) 1998-08-13 1999-08-11 Phenyl yanthine derivatives.

Country Status (36)

Country Link
US (3) US6608069B1 (OSRAM)
EP (1) EP1104422B1 (OSRAM)
JP (3) JP3631961B2 (OSRAM)
KR (1) KR20010085369A (OSRAM)
CN (2) CN1251676C (OSRAM)
AP (1) AP1408A (OSRAM)
AR (1) AR020154A1 (OSRAM)
AT (1) ATE259810T1 (OSRAM)
AU (1) AU775819B2 (OSRAM)
BR (1) BR9913020A (OSRAM)
CA (1) CA2340350A1 (OSRAM)
CO (1) CO5130007A1 (OSRAM)
DE (1) DE69914921T2 (OSRAM)
DK (1) DK1104422T3 (OSRAM)
EA (1) EA004139B1 (OSRAM)
EE (1) EE04721B1 (OSRAM)
ES (1) ES2215399T3 (OSRAM)
GB (1) GB9817623D0 (OSRAM)
HU (1) HUP0103637A3 (OSRAM)
ID (1) ID28723A (OSRAM)
IL (1) IL141318A0 (OSRAM)
IS (1) IS5843A (OSRAM)
MA (1) MA26673A1 (OSRAM)
MY (1) MY133393A (OSRAM)
NO (1) NO20010715L (OSRAM)
NZ (1) NZ509778A (OSRAM)
PE (1) PE20000952A1 (OSRAM)
PL (1) PL346055A1 (OSRAM)
PT (1) PT1104422E (OSRAM)
SI (1) SI1104422T1 (OSRAM)
SK (1) SK2222001A3 (OSRAM)
TR (1) TR200100448T2 (OSRAM)
TW (1) TWI224598B (OSRAM)
WO (1) WO2000009507A1 (OSRAM)
YU (1) YU11601A (OSRAM)
ZA (1) ZA200101186B (OSRAM)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
AU2002248910A1 (en) * 2000-11-17 2002-05-27 Idenix (Cayman) Limited Methods for inhibiting the transmission of HIV using topically applied substituted 6-benzyl-4-oxopyrmidines
JP2004523559A (ja) * 2001-02-28 2004-08-05 スミスクライン ビーチャム コーポレーション 過敏性腸症候群および機能性胃腸症の治療方法
EP1418882A1 (en) 2001-08-24 2004-05-19 Unilever N.V. Oral composition comprising an alkylhydroxybenzoate
CN100467469C (zh) 2001-11-09 2009-03-11 Cv医药有限公司 A2b腺苷受体拮抗剂
US7125993B2 (en) 2001-11-09 2006-10-24 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US6977300B2 (en) 2001-11-09 2005-12-20 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US7317017B2 (en) 2002-11-08 2008-01-08 Cv Therapeutics, Inc. A2B adenosine receptor antagonists
US20040072848A1 (en) * 2002-02-26 2004-04-15 Huber Brian E Methods of treating irritable bowel syndrome and functional dyspepsia
JP4491344B2 (ja) 2002-06-17 2010-06-30 グラクソ グループ リミテッド 肝ｘ受容体アゴニストとしてのプリン誘導体
WO2005021548A2 (en) * 2003-08-25 2005-03-10 Adenosine Therapeutics, Llc Substituted 8-heteroaryl xanthines
GB0324086D0 (en) * 2003-10-14 2003-11-19 Glaxo Group Ltd Process for preparing a co-precipitate of a non-crystalline solid drug substance
WO2006004903A2 (en) * 2004-06-28 2006-01-12 Atherogenics, Inc. 1,2-bis-(substituted-phenyl)-2-propen-1-ones and pharmaceutical compositions thereof
US7598379B2 (en) * 2005-02-25 2009-10-06 Pgx Health, Llc Methods for the synthesis of unsymmetrical cycloalkyl substituted xanthines
US7618962B2 (en) * 2005-02-25 2009-11-17 Pgx Health, Llc Pyrazolyl substituted xanthines
US7884100B2 (en) * 2006-06-16 2011-02-08 Pgxhealth, Llc Substituted 8-[6-amino-3-pyridyl]xanthines
US20120108614A1 (en) * 2008-05-14 2012-05-03 Chong Jayhong A Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009140517A1 (en) 2008-05-14 2009-11-19 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2010039289A2 (en) 2008-05-14 2010-04-08 Hydra Biosciences, Inc. Compounds and compositions for treating chemical warfare agent-induced injuries
WO2009146406A1 (en) * 2008-05-30 2009-12-03 Genentech, Inc. Purine pi3k inhibitor compounds and methods of use
CN102260260B (zh) * 2010-05-24 2014-08-06 中国科学院上海药物研究所 8-苯基黄嘌呤类化合物、其制备方法、包含该化合物的药物组合物及其用途
CN102993203B (zh) * 2011-09-09 2015-11-25 温州医学院 8-苯基黄嘌呤类衍生物的制备及应用
US9502952B2 (en) 2012-10-12 2016-11-22 Persimmon Technologies, Corp. Hybrid motor
KR20160005365A (ko) 2013-05-10 2016-01-14 님버스 아폴로, 인코포레이티드 Acc 억제제 및 이의 용도
EA201591959A1 (ru) 2013-05-10 2016-03-31 Нимбус Аполло, Инк. Ингибиторы акк и их применение
HK1221411A1 (zh) 2013-05-10 2017-06-02 Gilead Apollo, Inc. Acc抑制剂和其用途
WO2014182950A1 (en) 2013-05-10 2014-11-13 Nimbus Apollo, Inc. Acc inhibitors and uses thereof
EP4389749A1 (en) * 2022-12-20 2024-06-26 invIOs GmbH Substituted 3,7-dihydro-1h-purine-2,6-diones and use thereof
IL320958A (en) 2022-12-20 2025-07-01 Invios Gmbh 3,7-DIHYDRO-1 H-PURINE-2,6-DIONES TRANSFORMERS AND THEIR USES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004280A1 (en) * 1994-08-01 1996-02-15 The Wellcome Foundation Limited Phenyl xanthine derivatives
WO1998035966A1 (en) * 1997-02-14 1998-08-20 Glaxo Group Limited Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4442125A (en) * 1978-06-26 1984-04-10 Oxford Hill, Ltd. Process for detaching or preventing attachment of microorganisms to a surface
GB8510758D0 (en) 1985-04-27 1985-06-05 Wellcome Found Compounds
US4968672A (en) * 1987-01-02 1990-11-06 The United States Of America As Represented By The Department Of Health And Human Services Adenosine receptor prodrugs
US5015647A (en) 1987-04-24 1991-05-14 Burroughs Wellcome Co. Method for treating viral infections
GB8826595D0 (en) 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
GB8906792D0 (en) 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL100088A (en) 1990-11-21 1995-07-31 Smithkline Beecham Corp FNT inhibitor preparations containing histogenic transducts converted at positions 1, 3, and 8
GB9210839D0 (en) 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
TW252044B (OSRAM) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
JP2613355B2 (ja) 1992-09-28 1997-05-28 協和醗酵工業株式会社 パーキンソン氏病治療剤
WO1995013094A1 (en) * 1993-11-10 1995-05-18 Bristol-Myers Squibb Company Treatment of bacterially-induced inflammatory diseases
US5395831A (en) 1994-04-08 1995-03-07 American Home Products Corporation Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone
DE19535504A1 (de) 1995-09-25 1997-03-27 Bayer Ag Substituierte Xanthine
WO1997034616A1 (en) 1996-03-18 1997-09-25 Medical Science Systems, Inc. A method for periodontal disease treatment
DK0812844T3 (da) 1996-06-07 2003-02-17 Hoechst Ag Anvendelse af theophyllinderivater til behandling og profylakse af choktilstande, nye xanthinforbindelser og fremgangsmåder til deres fremstilling
US6096707A (en) * 1997-07-11 2000-08-01 Biotie Therapies Ltd. Integrin binding peptide and use thereof
US6117878A (en) * 1998-02-24 2000-09-12 University Of Virginia 8-phenyl- or 8-cycloalkyl xanthine antagonists of A2B human adenosine receptors
WO1999043673A1 (en) 1998-02-26 1999-09-02 Zenyaku Kogyo Kabushiki Kaisha 1-azaindolizine derivatives
GB9817623D0 (en) * 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
RU2002119574A (ru) 1999-12-23 2004-01-10 Нитромед, Инк. (Us) Нитрозированные и нитрозилированные ингибиторы циклооксигеназы-2, композиции на их основе и способы их применения
US20020006915A1 (en) * 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
US6751206B1 (en) 2000-06-29 2004-06-15 Qualcomm Incorporated Method and apparatus for beam switching in a wireless communication system

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996004280A1 (en) * 1994-08-01 1996-02-15 The Wellcome Foundation Limited Phenyl xanthine derivatives
WO1998035966A1 (en) * 1997-02-14 1998-08-20 Glaxo Group Limited Substituted (1,3-bis(cyclohexylmethyl)-1,2,3,6-tetrahydro-2,6-dioxo-9h-purin-8-yl)phenyl derivatives, their preparation and their use in the treatment of inflammatory conditions and immune disorders

Also Published As

Publication number Publication date
EP1104422A1 (en) 2001-06-06
TWI224598B (en) 2004-12-01
CN1251676C (zh) 2006-04-19
ZA200101186B (en) 2002-02-12
IS5843A (is) 2001-02-09
WO2000009507A1 (en) 2000-02-24
AR020154A1 (es) 2002-04-10
US6770267B2 (en) 2004-08-03
HK1035195A1 (en) 2001-11-16
ID28723A (id) 2001-06-28
SK2222001A3 (en) 2001-12-03
MY133393A (en) 2007-11-30
EA200100127A1 (ru) 2001-10-22
EE200100083A (et) 2002-06-17
PT1104422E (pt) 2004-06-30
BR9913020A (pt) 2001-05-08
CN1515571A (zh) 2004-07-28
JP2004115534A (ja) 2004-04-15
CA2340350A1 (en) 2000-02-24
DK1104422T3 (da) 2004-06-14
PL346055A1 (en) 2002-01-14
GB9817623D0 (en) 1998-10-07
JP2004137251A (ja) 2004-05-13
DE69914921D1 (en) 2004-03-25
TR200100448T2 (tr) 2001-09-21
YU11601A (sh) 2004-03-12
DE69914921T2 (de) 2004-12-23
US6608069B1 (en) 2003-08-19
PE20000952A1 (es) 2000-09-29
CN1323309A (zh) 2001-11-21
ATE259810T1 (de) 2004-03-15
HUP0103637A2 (en) 2002-06-29
AU775819B2 (en) 2004-08-19
HUP0103637A3 (en) 2002-10-28
US20040034020A1 (en) 2004-02-19
NZ509778A (en) 2003-08-29
US20030032804A1 (en) 2003-02-13
CN1149215C (zh) 2004-05-12
CO5130007A1 (es) 2002-02-27
KR20010085369A (ko) 2001-09-07
SI1104422T1 (en) 2004-06-30
JP2002522542A (ja) 2002-07-23
EA004139B1 (ru) 2004-02-26
AU5732399A (en) 2000-03-06
NO20010715D0 (no) 2001-02-12
IL141318A0 (en) 2002-03-10
NO20010715L (no) 2001-04-02
ES2215399T3 (es) 2004-10-01
EE04721B1 (et) 2006-10-16
JP3631961B2 (ja) 2005-03-23
EP1104422B1 (en) 2004-02-18
MA26673A1 (fr) 2004-12-20
AP2001002071A0 (en) 2001-03-31

Similar Documents

Publication Publication Date Title
AP1408A (en) Phenyl yanthine derivatives.
AP2000001881A0 (en) 2-(Purine-9-YL)-tetrahydrofuran-3,4 4-diol derivatives.
DE69522947D1 (en) Phenylxanthin-derivate
HK1038744A1 (zh) 用於治療炎性疾病的化合物
GB9813540D0 (en) Chemical compounds
MY121294A (en) Novel hexanoic acid derivatives.
BG104729A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
TW515798B (en) Heterocyclic compounds for inhibition of gastric acid secretion, processes for their preparation and pharmaceutical compositions thereof
MY147449A (en) 2, 4-pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders
BG105880A (en) Compounds useful as anti-inflammatory agents
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
SE9902987D0 (sv) Novel compounds
AP2001002088A0 (en) 4,4-Biarylpiperidine derivatives with opiod receptor activity.
BG103947A (en) Derivatives of 9-oxymerythromycin
MY120976A (en) 2-amino-6-(2-substituted-4-phenoxy)- substituted- pyridines
BG106155A (en) Novel derivatives and analogues of galanthamin
DK1057828T3 (da) Orale trovafloxacin-suspensioner
IL151201A0 (en) Alkylated imidazopyridine derivatives and pharmaceutical compositions containing the same
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
MY133125A (en) Novel dihydroxyhexanoic acid derivatives
NZ324380A (en) Therapeutic benzimidazole compounds and their use in treatment of virus infections
IL141325A0 (en) Tan-1057 derivatives
IL159241A0 (en) Use of branched-chain fatty acids and derivatives thereof for the treatment of pain
BG103260A (en) The application of 1-hydroxy-2-pyridons for the treatment of seborrheic dermatitis